arrow
R

Ruth Stuckey

miguel servet university hospital
H指数:13
被引数:731

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of thrombosis on disease progression, cancer and mortality in patients with essential thrombocythemia and polycythemia vera

血栓形成对原发性血小板增多症和真性红细胞增多症患者疾病进展、癌症和死亡率的影响

2026-05-010
OA
Response to therapy and prognosis according to molecular characterization in CALR-mutated essential thrombocythemia

CALR突变型原发性血小板增多症的分子特征与治疗反应及预后

2026-03-230
OAAI
The germline challenge in allogeneic transplantation: from donor selection to outcomes

同种异体移植中的种系挑战:从供体选择到结局

2026-03-040
PRE
Copy-Neutral Loss of Heterzygosity in Myelofibrosis: Parallel Evaluation with Optical Genome Mapping and Single-Nucleotide Polymorphism Arrays
2026-01-300
OAAI
OPTICAL GENOME MAPPING IN MYELOFIBROSIS: ENHANCING PROGNOSTIC ACCURACY THROUGH HIGH-RESOLUTION GENOMIC PROFILING.

光学基因组作图在骨髓纤维化中的应用:通过高分辨率基因组分析提高预后准确性。

2025-10-300
OAAI
Coexisting Myeloproliferative and Lymphoid Neoplasms: A European Multicenter Retrospective Study

共存骨髓增殖性肿瘤和淋巴性肿瘤:一项欧洲多中心回顾性研究

2025-10-170
OAAI
ACQUISITION OF MOLECULAR ALTERATIONS IN UNTREATED-LOW RISK MYELODYSPLASTIC SYNDROMES IS ASSOCIATED WITH POOR PROGNOSIS

未治疗低风险骨髓增生异常综合征中分子改变的发生与不良预后相关

2025-09-010
PRE
Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study

momelotinib在伴有贫血的骨髓纤维化患者中的真实世界结局:MOMGEMFIN研究的结果

2025-04-171
OA
Molecular response with asciminib 20 mg QD in a patient intolerant to multiple TKIs

对多种TKIs不耐受的患者使用asciminib 20 mg QD的分子反应

2025-04-010
OAAI
Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia

momelotinib 作为替代其他 JAK 抑制剂在贫血性骨髓纤维化患者中的真实世界疗效

BLOOD
IF23.1
2024-11-051
PRE
Prognostic Value of Response to First-Line Hydroxyurea According to Ipset Stratification in Essential Thrombocythemia

根据Ipset分层,对原发性血小板增多症患者一线羟基脲治疗反应的预后价值

BLOOD
IF23.1
2024-11-050
PRE
Characteristics of Pediatric and Adolescents and Young Adults (AYA) with Chronic Myeloid Leukemia: Data from the Canarian Registry of CML

儿科、青少年和年轻成人(AYA)慢性髓性白血病患者的特征:来自加那利慢性髓性白血病登记数据库的数据

BLOOD
IF23.1
2024-11-050
PRE
Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia
LEUKEMIA
IF13.4
2024-09-270
PRE
DNMT3A/TET2/ASXL1 Mutations are an Age-independent Thrombotic Risk Factor in Polycythemia Vera Patients: An Observational Study

DNMT3A/TET2/ASXL1突变是真性红细胞增多症患者中与年龄无关的血栓形成危险因素: 一项观察性研究

2024-01-305
OAAI
Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia
2023-08-017
OAAI
CNL and aCML should be considered as a single entity based on molecular profiles and outcomes
2023-04-2614
OAAI
Genetic Testing at Diagnosis Has Prognostic Value in Patients with Chronic Lymphocytic Leukemia including at Early Stages

诊断时的基因检测对包括早期在内的慢性淋巴细胞白血病患者具有预后价值

2022-07-250
OAAI